Prostatype Genomics
10,7
SEK
-3,6 %
PROGEN
First North Stockholm
Medical Equipment & Services
Health Care
3 investorer følger denne virksomhed
-3,6%
-3,6%
+42,67%
-17,69%
-14,04%
-76,02%
-98,76%
-
-98,41%
Prostatype Genomics is active in medical technology. The company specializes in the development of medical-technical genetic tests that are used for identification, analysis, and further follow-up of prostate cancer. In addition to the main business, service and associated ancillary services are also offered. The operations are found worldwide with the largest presence in the Nordic market.
Læs mereMarkedsværdi
73,14 mio. SEK
Aktieomsætning
181,87 t SEK
Omsætning
1,36 mio.
EBIT %
-2.886,03 %
P/E
-
Udbytteafkast, %
-
Finanskalender
13.2
2025
Årsrapport '24
ViserAlle indholdstyper
New shares from the exercise of Prostatype Genomics AB’s warrants of series TO 4 is now registered at the Swedish Companies Registration Office
Health economics study with Prostatype® peer-reviewed and approved for publishing in renown scientific journal
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools